Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SYN818 monotherapy in relapsed or refractory lymphoma and multiple myeloma
CTR20261853Phase 2Active
- Sponsor
- SynRx Therapeutics
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SYN818 in lymphoma, multiple myeloma (MM), sponsored by SynRx Therapeutics. Started May 2026; status: active.
02
Drugs
SYN818
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on CTR20261853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261853.